Benchmark study reveals Q40 sequencing significantly boosts sensitivity for somatic mutations, implying reduced costs in precision oncology.
Abstract Background High quality scores (Q-scores) are critical for sequencing accuracy, yet the impact of Q40-achieving sequencing technologies (99.99% accuracy) on detecting subtle biological variations remains unvalidated. Results Using a comprehensive set of well-established DNA/RNA reference materials (Quartet, NIST-RM8398, SEQC2-HCC1395/BL, MAQC, and ERCC), we benchmarked Q40 sequencing (Element AVITI) against the conventional Q30 standard (Illumina NovaSeq 6000). Q40 reduced required sequencing depth by 33.3% while maintaining accuracy for germline variants (20× vs. 30×) and somatic SNV/InDels (60× vs. 90×). Crucially, Q40 enhanced sensitivity for low-frequency somatic mutations (VAF ≤ 0.2) by 33.3% and 12.6-fold higher CNV detection reproducibility (77.7% vs. 5.7%) with Q40 at 30× depth, directly reducing per-sample costs by 30-50%. In addition, Q40 improved the discriminatory resolution between biological samples with 13.1% SNR enhancement. Conclusions This work establishes Q40 as a cost-effective solution for enhancing rare variant detection in precision oncology applications such as liquid biopsy and minimal residual disease monitoring.
No takes yet. Share an insight, caveat, or question.
Duan et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: